Cargando…
A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes
OBJECTIVE: Silent myocardial infarction (MI) is a prevalent finding in patients with type 2 diabetes and is associated with significant mortality and morbidity. Late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR) is the most validated technique for detection of silent MI, bu...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377587/ https://www.ncbi.nlm.nih.gov/pubmed/27300573 http://dx.doi.org/10.1210/jc.2016-1318 |
_version_ | 1782519338854514688 |
---|---|
author | Swoboda, Peter P. McDiarmid, Adam K. Erhayiem, Bara Haaf, Philip Kidambi, Ananth Fent, Graham J. Dobson, Laura E. Musa, Tarique A. Garg, Pankaj Law, Graham R. Kearney, Mark T. Barth, Julian H. Ajjan, Ramzi Greenwood, John P. Plein, Sven |
author_facet | Swoboda, Peter P. McDiarmid, Adam K. Erhayiem, Bara Haaf, Philip Kidambi, Ananth Fent, Graham J. Dobson, Laura E. Musa, Tarique A. Garg, Pankaj Law, Graham R. Kearney, Mark T. Barth, Julian H. Ajjan, Ramzi Greenwood, John P. Plein, Sven |
author_sort | Swoboda, Peter P. |
collection | PubMed |
description | OBJECTIVE: Silent myocardial infarction (MI) is a prevalent finding in patients with type 2 diabetes and is associated with significant mortality and morbidity. Late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR) is the most validated technique for detection of silent MI, but is time-consuming, costly, and requires administration of intravenous contrast. We therefore planned to develop a simple and low-cost population screening tool to identify those at highest risk of silent MI validated against the CMR reference standard. METHODS: A total of 100 asymptomatic patients with type 2 diabetes underwent electrocardiogram (ECG), echocardiography, biomarker assessment, and CMR at 3.0T including assessment of left ventricular ejection fraction and LGE. Global longitudinal strain from two- and four-chamber cines was measured using feature tracking. RESULTS: A total of 17/100 patients with no history of cardiovascular disease had silent MI defined by LGE in an infarct pattern on CMR. Only four patients with silent MI had Q waves on ECG. Patients with silent MI were older (65 vs 60, P = .05), had lower E/A ratio (0.75 vs 0.89, P = .004), lower GLS (–15.2% vs –17.7%, P = .004), and higher amino-terminal pro brain natriuretic peptide (106 ng/L vs 52 ng/L, P = .003). A combined risk score derived from these four factors had an area under the receiver operating characteristic curve of 0.823 (0.734–0.892), P < .0001. A score of more than 3/5 had 82% sensitivity and 72% specificity for silent MI. CONCLUSIONS: Using measures that can be derived in an outpatient clinic setting, we have developed a novel screening tool for the detection of silent MI in type 2 diabetes. The screening tool had significantly superior diagnostic accuracy than current ECG criteria for the detection of silent MI in asymptomatic patients. |
format | Online Article Text |
id | pubmed-5377587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-53775872017-09-01 A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes Swoboda, Peter P. McDiarmid, Adam K. Erhayiem, Bara Haaf, Philip Kidambi, Ananth Fent, Graham J. Dobson, Laura E. Musa, Tarique A. Garg, Pankaj Law, Graham R. Kearney, Mark T. Barth, Julian H. Ajjan, Ramzi Greenwood, John P. Plein, Sven J Clin Endocrinol Metab Original Article OBJECTIVE: Silent myocardial infarction (MI) is a prevalent finding in patients with type 2 diabetes and is associated with significant mortality and morbidity. Late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR) is the most validated technique for detection of silent MI, but is time-consuming, costly, and requires administration of intravenous contrast. We therefore planned to develop a simple and low-cost population screening tool to identify those at highest risk of silent MI validated against the CMR reference standard. METHODS: A total of 100 asymptomatic patients with type 2 diabetes underwent electrocardiogram (ECG), echocardiography, biomarker assessment, and CMR at 3.0T including assessment of left ventricular ejection fraction and LGE. Global longitudinal strain from two- and four-chamber cines was measured using feature tracking. RESULTS: A total of 17/100 patients with no history of cardiovascular disease had silent MI defined by LGE in an infarct pattern on CMR. Only four patients with silent MI had Q waves on ECG. Patients with silent MI were older (65 vs 60, P = .05), had lower E/A ratio (0.75 vs 0.89, P = .004), lower GLS (–15.2% vs –17.7%, P = .004), and higher amino-terminal pro brain natriuretic peptide (106 ng/L vs 52 ng/L, P = .003). A combined risk score derived from these four factors had an area under the receiver operating characteristic curve of 0.823 (0.734–0.892), P < .0001. A score of more than 3/5 had 82% sensitivity and 72% specificity for silent MI. CONCLUSIONS: Using measures that can be derived in an outpatient clinic setting, we have developed a novel screening tool for the detection of silent MI in type 2 diabetes. The screening tool had significantly superior diagnostic accuracy than current ECG criteria for the detection of silent MI in asymptomatic patients. Endocrine Society 2016-06-14 /pmc/articles/PMC5377587/ /pubmed/27300573 http://dx.doi.org/10.1210/jc.2016-1318 Text en Copyright © 2016 Endocrine Society https://creativecommons.org/licenses/by/4.0/ This article has been published under the terms of the Creative Commons Attribution License (CC BY; https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Swoboda, Peter P. McDiarmid, Adam K. Erhayiem, Bara Haaf, Philip Kidambi, Ananth Fent, Graham J. Dobson, Laura E. Musa, Tarique A. Garg, Pankaj Law, Graham R. Kearney, Mark T. Barth, Julian H. Ajjan, Ramzi Greenwood, John P. Plein, Sven A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes |
title | A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes |
title_full | A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes |
title_fullStr | A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes |
title_full_unstemmed | A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes |
title_short | A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes |
title_sort | novel and practical screening tool for the detection of silent myocardial infarction in patients with type 2 diabetes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377587/ https://www.ncbi.nlm.nih.gov/pubmed/27300573 http://dx.doi.org/10.1210/jc.2016-1318 |
work_keys_str_mv | AT swobodapeterp anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT mcdiarmidadamk anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT erhayiembara anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT haafphilip anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT kidambiananth anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT fentgrahamj anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT dobsonlaurae anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT musatariquea anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT gargpankaj anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT lawgrahamr anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT kearneymarkt anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT barthjulianh anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT ajjanramzi anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT greenwoodjohnp anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT pleinsven anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT swobodapeterp novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT mcdiarmidadamk novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT erhayiembara novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT haafphilip novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT kidambiananth novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT fentgrahamj novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT dobsonlaurae novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT musatariquea novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT gargpankaj novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT lawgrahamr novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT kearneymarkt novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT barthjulianh novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT ajjanramzi novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT greenwoodjohnp novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes AT pleinsven novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes |